Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Pharmacokinetics

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40262-016-0428-xPMID 27324191
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

  2014cited by this paper
• Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

  2014influential reference
• Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012

  2013cited by this paper
• Therapeutic drug monitoring of amikacin in septic patients

  2013cited by this paper
• Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients

  2013influential reference
• Antibacterial Dosing in Intensive Care Pharmacokinetics, Degree of Disease and Pharmacodynamics of Sepsis

  2012cited by this paper
• Therapeutic drug monitoring of antimicrobials.

  2012cited by this paper
• Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid

  2011cited by this paper
• Population pharmacokinetics of amikacin in a Korean clinical population.

  2011influential reference
• Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid

  2011cited by this paper
• Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia

  2011cited by this paper
• Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

  2010cited by this paper
• Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients

  2010cited by this paper
• A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• International study of the prevalence and outcomes of infection in intensive care units

  2009cited by this paper
• International study of the prevalence and outcomes of infection in intensive care units.

  2009cited by this paper
• The Role of Rapid Diagnostic Tests in Managing Malaria

  2009cited by this paper
• Facilitation of Drug Evaluation in Children by Population Methods and Modelling

  2008cited by this paper
• Are Population Pharmacokinetic and/ or Pharmacodynamic Models Adequately Evaluated?

  2007cited by this paper
• Antibacterial Dosing in Intensive Care

  2006cited by this paper
• Antimicrobial Therapy in Critically Ill Patients

  2005cited by this paper
• Gentamicin volume of distribution in critically ill septic patients

  2005cited by this paper
• Pharmacokinetics of antibiotics in critically ill patients

  2005cited by this paper
• Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness

  2004cited by this paper
• Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.

  2004influential reference
• Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia

  2004cited by this paper
• Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic Shock

  2002cited by this paper
• Immunotherapy of sepsis.

  2001cited by this paper
• Pharmacokinetics of Drugs Used in Critically Ill Adults

  1998cited by this paper
• Influence of Clinical Diagnosis in the Population Pharmacokinetics of Amikacin in Intensive Care Unit Patients

  1998influential reference
• Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.

  1997influential reference
• Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis.

  1997cited by this paper
• Population pharmacokinetics of amikacin in critically ill patients

  1996influential reference
• Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm

  1995cited by this paper
• Aminoglycosides--50 years on.

  1995cited by this paper
• A suggested approach to once-daily aminoglycoside dosing.

  1995cited by this paper
• Aminoglycoside volume of distribution in postoperative patients with septic shock.

  1993cited by this paper
• Aminoglycoside Dosing Considerations in Intensive Care Unit Patients

  1993cited by this paper
• Immunotherapy in sepsis

  1992cited by this paper
• Amikacin Pharmacokinetics: Wide Interpatient Variation in 98 Patients

  1991cited by this paper
• Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity

  1990cited by this paper
• The Altered Pharmacokinetics and Pharmacodynamics of Drugs Commonly Used in Critically Ill Patients

  1988cited by this paper
• Variability in aminoglycoside pharmacokinetics in critically ill surgical patients.

  1988cited by this paper
• Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

  1987cited by this paper
• CLINICAL PHARMACOKINETICS, TOXICITY AND COST EFFECTIVENESS ANALYSIS OF AMINOGLYCOSIDES AND AMINOGLYCOSIDE DOSING SERVICES

  1987cited by this paper
• Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Second Edition

  1987cited by this paper
• Effect of mechanical ventilation on hepatic drug pharmacokinetics.

  1986cited by this paper
• Variability in aminoglycoside pharmacokinetics in critically ill surgical patients

  1986cited by this paper
• Respiratory Support and Renal Function

  1984cited by this paper
• Respiratory support and renal function.

  1981cited by this paper
• Pharmacokinetics of Amikacin During Hemodialysis and Peritoneal Dialysis

  1977cited by this paper
• Modelling of individual pharmacokinetics for computer-aided drug dosage.

  1972cited by this paper
• Continuous patient monitoring with a small digital computer.

  1972cited by this paper

• Amikacin Exposure in MDR-TB Patients in Uganda: Revisiting Old Drugs in a New Era of Resistance – A Pharmacokinetic Assessment

  2026cites this paper
• Amikacin toxicity revisited: pentoxifylline offers protection in high-risk treatment scenarios

  2025cites this paper
• Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching Hospital

  2025influential citation
• Anti-infectives in Pediatric Patients with Cystic Fibrosis: A Comprehensive Review of Population Pharmacokinetic Analyses

  2025cites this paper
• A Bayesian Framework for Optimizing Amikacin Therapy in Critically Ill Patients With Cancer.

  2025cites this paper
• Amikacin Dosing Adjustment in Critically Ill Oncologic Patients: A Study with Real-World Patients, PBPK Analysis, and Digital Twins

  2025cites this paper
• Amikacin therapeutic drug monitoring: Evaluation of therapy performance and analytical techniques in a developing country setting.

  2025cites this paper
• Simulation-Based Assessment of Empirical Amikacin Dosing in High-Risk Adults With Febrile Neutropenia and Hematological Malignancies Using Population Pharmacokinetic Modeling.

  2025cites this paper
• A simulation study on model‐informed precision dosing of amikacin for achieving target area under the concentration–time curve

  2024cites this paper
• Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models

  2024cites this paper
• Impact of duration of infusion on estimated blood amikacin levels: A study at the Central General Hospital in Yogyakarta, Indonesia

  2024cites this paper
• The Role of Some Antibiotics on Male and Female Urinary Tract Infections

  2024cites this paper
• Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable?

  2023cites this paper
• Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach

  2023cites this paper
• Pharmacokinetics of Amikacin in Eye Media Using Various Drugs

  2023cites this paper
• Individualized antibiotic dosage regimens for patients with augmented renal clearance

  2023cites this paper
• Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study

  2023cites this paper
• Malaria and typhoid fever among patients presenting with febrile illnesses in Ga West Municipality, Ghana

  2023cites this paper
• Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration.

  2023cites this paper
• Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients

  2023cites this paper
• Risk Factors Associated with Suboptimal Tobramycin Levels in the Medical Intensive Care Unit

  2022cites this paper
• Malaria and typhoid fever coinfection among patients presenting with febrile illnesses in Ga West Municipality, Ghana

  2022cites this paper
• Amikacin pharmacokinetics in elderly patients with severe infections.

  2022cites this paper
• Pharmacokinetic and pharmacodynamic considerations of antibiotics and antifungals in liver transplantation recipients

  2022cites this paper
• Thymoquinone ameliorates amikacin induced oxidative damage in rat brain tissue

  2022cites this paper
• Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose

  2022cites this paper
• Synergistic effect of low‐frequency ultrasound and antibiotics on the treatment of Klebsiella pneumoniae pneumonia in mice

  2022cites this paper
• Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant Klebsiella pneumoniae strains

  2022cites this paper
• Bacterial antibiotic resistance among cancer inpatients in China: 2016-2020.

  2022cites this paper
• Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation

  2022cites this paper
• Malaria and typhoid fever coinfection among patients presenting with febrile illnesses in Ga West 2 Municipality,

  2022cites this paper
• Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review

  2021cites this paper
• The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients

  2021cites this paper
• In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae.

  2021cites this paper
• Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?

  2021cites this paper
• Changes in haemato-biochemical and urine indices in response to the intravenous administration of amikacin

  2021cites this paper
• Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses

  2021influential citation
• Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children

  2021cites this paper
• Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis

  2021cites this paper
• Relationship between amikacin pharmacokinetics and biological parameters associated with organ dysfunction: a case series study of critically ill patients with intra-abdominal sepsis

  2021cites this paper
• Therapeutic drug monitoring of amikacin: quantification in plasma by liquid chromatography-tandem mass spectrometry and work experience of clinical pharmacists

  2021cites this paper
• Population pharmacokinetic evaluation and optimisation

  2020cites this paper
• Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions

  2020cites this paper
• Dried plasma spots for therapeutic monitoring of amikacin: Validation of an UHPLC-MS/MS assay and pharmacokinetic application.

  2020cites this paper
• Pharmacocinétique de population de l'amikacine chez les patients de réanimation traités par laparostomie avec pansement aspiratif

  2020cites this paper
• Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy

  2020cites this paper
• Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach.

  2020cites this paper
• Dual-responsive injectable hydrogels encapsulating drug-loaded micelles for on-demand antimicrobial activity and accelerated wound healing.

  2020cites this paper
• External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients

  2020cites this paper
• Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?

  2020cites this paper
• Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing

  2020cites this paper
• Impact of Therapeutic Drug Monitoring on Once-daily Regimen of Amikacin in Patients with Urinary Tract Infection: A Prospective Observational Study.

  2020cites this paper
• Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections.

  2020cites this paper
• Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen.

  2019cites this paper
• Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children

  2019cites this paper
• Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis

  2019cites this paper
• Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients

  2019cites this paper
• Pediatric Pulmonology

  2019cites this paper
• Ready for TDM: Simultaneous quantification of amikacin, vancomycin and creatinine in human plasma employing ultra-performance liquid chromatography-tandem mass spectrometry.

  2019cites this paper
• Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution

  2019cites this paper
• Clinical applications of the naturally occurring or synthetic glycosylated low molecular weight drugs.

  2019cites this paper
• Evaluation of Amikacin Pharmacokinetics in Critically Ill Patients with Intra-abdominal Sepsis

  2019cites this paper
• Evaluation of Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Glomerular Filtration Rate and Amikacin Clearance During Early Rat Endotoxemia: Comparison with Traditional Endogenous and Exogenous Biomarkers

  2019cites this paper
• Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients.

  2018cites this paper
• Extended-Spectrum beta-lactamase production and antimicrobial susceptibility pattern of uropathogens in a Tertiary Hospital in Northwestern Nigeria

  2018cites this paper
• Augmented Renal Clearance

  2018cites this paper
• Determinants of amikacin first peak concentration in critically ill patients

  2018cites this paper
• Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients

  2017cites this paper
• Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

  2017cites this paper
• Amikacin: Uses, Resistance, and Prospects for Inhibition

  2017cites this paper
• Pharmacokinetics of Amikacin in Critical Care Patients on Extracorporeal Device

  2017cites this paper
• History of antimicrobial drug discovery: Major classes and health impact.

  2017cites this paper
• What’s new in multidrug-resistant pathogens in the ICU?

  2016cites this paper